Multi-tablet, Single-Tablet, or Long-Acting Antiretroviral Treatment for HIV: A Cross-sectional Study of Patient Preferences in the United States and Spain.
Alfredo Soler Carracedo, Vitor Oliveira, Jorge Saz and 3 others
PMID 35878049WHAT IT FOUND
In Spain, 61.9% preferred a two-month HIV injection; in the USA, 44.4% preferred a once-daily tablet.
Preference for injection was linked to recent diagnosis, dissatisfaction with current treatment, and prior injection experience.
Key findings
01In Spain, 61.9% preferred one injection every two months; in the USA, 44.4% preferred one tablet once a day.
02In the USA, 68.5% preferred oral ART; in Spain, 66.9% preferred injectable ART.
03When both sites were combined, preference for injectable ART was linked to recent diagnosis, dissatisfaction with current ART, and previous injection.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The USA site had 55 participants, and Spain had 141 of 1,100 eligible candidates, a 12.8% participation rate. Participants were already interested in research, and the paper notes this may make them more open to novel treatment. The combined sample was mostly male, homosexual, and white, so findings may not apply to other groups. Comorbidities and total pill burden were not measured, so reasons for preferring oral treatment were not studied. The design was cross-sectional and relied on self-report, so it cannot show causation or why preferences differ. No qualitative component was included, so detailed reasons for preference were not obtained.
The easy way to misread this
Do not read these preferences as evidence that long-acting injection is clinically better or that nurses should routinely recommend it; this survey measured stated preference, not treatment outcomes, and acceptance differed by country.